Soleno Therapeutics’ Financial Challenges: Navigating Risks in VYKAT XR Commercialization

Soleno Therapeutics (SLNO) has disclosed a new risk, in the Accounting & Financial Operations category.

Soleno Therapeutics faces significant business risks as it embarks on generating product revenue, particularly with its recent commercialization of VYKAT XR. The company’s ability to achieve and maintain profitability is contingent upon successfully navigating a multitude of challenges, including establishing a robust commercial organization, achieving market acceptance, and securing reliable manufacturing and distribution partnerships. Additionally, Soleno must overcome regulatory hurdles, protect its intellectual property, and manage potential increases in expenses due to unforeseen regulatory demands or clinical trial requirements. The uncertainty surrounding these factors poses a substantial risk to Soleno’s financial stability and operational continuity.

The average SLNO stock price target is $117.36, implying 150.39% upside potential.

To learn more about Soleno Therapeutics’ risk factors, click here.